Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Polymyxin B (PMB) is an antibiotic used to treat gram-negative infections. It has known several adverse effects including nephrotoxicity specifically the development of acute kidney injury (AKI). This study aimed to determine the incidence and factors associated with the development of AKI and electrolyte imbalances among patients treated with Polymyxin B.
We conducted a retrospective cohort study using medical records of admitted patients from January to December 2022 with any type of infection given PMB. The occurrence of nephrotoxicity, defined as the development of either AKI or electrolyte imbalances (hypokalemia, hypomagnesemia, hyponatremia, hypocalcemia) was calculated as incidence rate while associated risk factors was determined using Cox proportional hazard.
Of the 202 patients included in the study, 192 (95.1%) developed nephrotoxicity, with 173 (85.6%) developed electrolyte imbalance. The most frequent electrolyte imbalance was hypomagnesemia (81.2%) followed by hypokalemia (68.3%). In the multivariate analysis of significant risk factors, dosing (HR 1.00 [95% CI 1.00-1.00], p=0.555) and duration of polymyxin B use were not associated with increased risk of nephrotoxicity. There were also no identified level of kidney function, comorbidity, and concomitant use of nephrotoxic agents which led to increased nephrotoxicity (HR 1.10 [95% CI 0.82-1.47], p=0.531). Lowest level of electrolytes recorded were as follows: hypokalemia 2.70 mmol/L (SD 0.44), hypomagnesemia 0.47 mmol/L (SD 0.12), hypocalcemia 1.98 mmol/L (SD 0.14), hyponatremia 127 mmol/L (SD 4.84).
In conclusion, this study shows the high incidence of AKI and electrolyte imbalances among patients treated with Polymyxin B, with the most frequent electrolyte abnormality being hypomagnesemia and hypokalemia. While the cumulative dose and duration of polymyxin, and the presence of multiple sites of infection and use of vancomycin had a statistically significant increased incidence of nephrotoxicity, none of the factors analyzed were shown to be independent risk factors for the occurrence of nephrotoxicity.
